Market revenue in 2023 | USD 775.1 million |
Market revenue in 2030 | USD 1,201.0 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Topical |
Fastest growing segment | Topical |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oral, Topical |
Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.66% in 2023. Horizon Databook has segmented the Asia Pacific onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to grow substantially during the forecast period due to a large patient pool. Asia Pacific consists of a blend of developing and developed economies. The increasing focus of industry participants such as Moberg Pharma AB on the region is anticipated to fuel market growth.
The increasing geriatric population, coupled with the rising number of diabetic patients across the region, is expected to boost the onychomycosis prevalence in Asia Pacific. According to the Asia/Pacific 2020 report published by the Organization for Economic Cooperation and Development (OECD), about 227 million individuals live with type 2 diabetes in Asia Pacific.
Furthermore, in some individuals with diabetes, the nails take on a yellowish shade, a sign of onychomycosis. Diabetic patients are at a higher risk of developing onychomycosis. Thus, the growing incidence of diabetes across the region is expected to increase the number of patients suffering from onychomycosis, which is expected to boost regional expansion.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific onychomycosis market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account